This concept eventually led to drugs like sitagliptin (approved 2006), but those would generally have less potent effects than direct GLP-1 agonists since GLP-1 levels only double or triple on DPP-4 inhibitors (and those drugs rely on some residual pancreatic function and meal stimulation) ( [59] )
Currently, formulary-exclusions from branded manufacturers have relegated generics of exenatide and of liraglutide (first-generation GLP-1s which have already gone generic) to the overlooked and unknown in spite of years of proven efficacy
Kapoor B, et al
Our goal is not just weight loss , but long-term health improvementhelping to reduce your risk of conditions such as type 2 diabetes, high blood pressure, and heart disease
For healthcare systems and policymakers, the evidence supports cautious optimism tempered by realistic acknowledgment of current limitations and the need for comprehensive approaches that address pharmacological efficacy, access, sustainability, and equity concerns